All In Biotech

Drug Trial Radar · NCT05959694

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

A Phase Ib/II Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory CLL/SLL.

Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

107

Planned (sponsor's estimate)

Start

Oct 11, 2023

Primary completion

Dec 2025

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • TQB3909 tabletDrug

    TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AE)Time frame: Up to 34 months.
  2. Severity of adverse events (AE)Time frame: Up to 34 months.
  3. Incidence of serious adverse events (SAE)Time frame: Up to 34 months.
  4. Severity of serious adverse events (SAE)Time frame: Up to 34 months.
  5. Incidence of abnormal laboratory examination indexes.Time frame: Up to 34 months.
  6. Severity of abnormal laboratory examination indexes.Time frame: Up to 34 months.
  7. Recommended phase II dose (RP2D)Time frame: Up to 18 months
  8. Objective remission rate (ORR) determined by Independent Review Committee (IRC)Time frame: Up to 34 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Anqing Municipal Hospital

    Anqing, Anhui, China · Recruiting

  • Gansu province Wuwei tumour hospital

    Wuwei, Gansu, China · Recruiting

  • Sun Yat-Sen University Cancer Canter

    Guangzhou, Guangdong, China · Recruiting

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China · Recruiting

  • Harbin first hospital

    Harbin, Heilongjiang, China · Recruiting

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Linyi people's hospital

    Linyi, Shandong, China · Recruiting

  • Tai 'an Central Hospital

    Tai’an, Shandong, China · Recruiting

  • Shanghai Tongren Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Peace Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • Affiliated hospital of southwest medical university

    Luzhou, Sichuan, China · Recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Recruiting

  • Yibin Second People's Hospital

    Yibin, Sichuan, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.